Clinical Trial Update: A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Jaktinib in the treatment of steroid-refractory acute graft-versus-host disease (aGVHD).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Jaktinib (jaktinib)

Snippet

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Conditions: Acute Graft-Versus-Host Disease | Phase 2 | Status: UNKNOWN